Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) (PAR-23-119)

Deadline: 9/25/2023

The National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) is pleased to announce a funding opportunity titled: Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) (PAR-23-119)

This funding opportunity uses NIH standard due dates.
                                          
Funding Opportunity Purpose

The purpose of this funding opportunity is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases. Prospective applicants are strongly encouraged to review the funding opportunity in its entirety, as there are some differences from its predecessor, and to contact the listed Scientific/Research Contacts in the early stages of formulating an application.

Last Updated 05/16/2023